Home/ Stocks/ TVTX

Travere Therapeutics, Inc. Common Stock

TVTX XNAS

$61.32 -1.09 (-1.75%) ▼ 15-min delayed

Open

$63.53

High

$63.71

Low

$60.67

Volume

1.23M

Market Cap

$5.89B

About Travere Therapeutics, Inc. Common Stock

Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. Its pipeline candidate, sparsentan, is an investigational product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN)-rare kidney disorders that often cause end-stage kidney disease. It is also advancing pegtibatinase, a novel investigational enzyme replacement therapy for the treatment of HCU, a genetic disorder caused by a deficiency in a pivotal enzyme essential to the body.

Sector: PHARMACEUTICAL PREPARATIONS Employees: 497 Website →

Key Financials

Period	Revenue	Net Income	EPS
Q2 2026	$169.58M	$-34,797,000	$-0.37
Q1 2026	$127.20M	$-37,102,000	$-0.40
FY 2025	$490.73M	$-25,546,000	$-0.29
Q3 2025	$164.86M	$25.71M	$0.29

Related Market News

No specific coverage for TVTX yet. Check out our latest market news or earnings calendar.

Get TVTX Alerts

Stay ahead with breaking news, price alerts, and expert analysis on Travere Therapeutics, Inc. Common Stock.

Disclaimer: This page is for informational purposes only. Stock data is delayed by at least 15 minutes. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.